Welcome to the UPF Digital Repository

HER-family ligands promote acquired resistance to trastuzumab in gastric cancer

Show simple item record

dc.contributor.author Sampera Borràs, Aïda, 1990-
dc.contributor.author Sánchez-Martín, Francisco Javier
dc.contributor.author Arpí Llucià, Oriol
dc.contributor.author Visa Turmo, Laura
dc.contributor.author Iglesias Coma, Mar
dc.contributor.author Menéndez, Silvia
dc.contributor.author Gaye, Élisabeth
dc.contributor.author Dalmases Massegú, Alba, 1982-
dc.contributor.author Clavé Safont, Sergi
dc.contributor.author Gelabert-Baldrich, Mariona
dc.contributor.author Tuxen Poulsen, Thomas
dc.contributor.author Kragh, Michael
dc.contributor.author Bellosillo Paricio, Beatriz
dc.contributor.author Albanell Mestres, Joan
dc.contributor.author Rovira Guerín, Ana
dc.contributor.author Rovira Guerín, Ana
dc.contributor.author Montagut Viladot, Clara
dc.date.accessioned 2020-03-04T08:25:13Z
dc.date.issued 2019
dc.identifier.citation Sampera A, Sánchez-Martín FJ, Arpí O, Visa L, Iglesias M, Menéndez S et al. HER-family ligands promote acquired resistance to trastuzumab in gastric cancer. Mol Cancer Ther. 2019 Nov;18(11):2135-45. DOI: 10.1158/1535-7163.MCT-19-0455
dc.identifier.issn 1535-7163
dc.identifier.uri http://hdl.handle.net/10230/43787
dc.description.abstract Despite the clinical benefit of trastuzumab, eventually all HER2-amplified gastric cancer tumors develop drug resistance. We aimed to identify molecular mechanisms of acquired resistance to trastuzumab in gastric cancer by using well-established cell line-based preclinical models, as well as samples from patients with HER2-positive gastric cancer treated with trastuzumab. We studied trastuzumab resistance in NCI-N87 and OE19, two gastric cancer cell lines that overexpress HER2 receptor and are trastuzumab sensitive. Differences at protein, DNA, and RNA levels between the parental and resistant cells were characterized and functional studies were performed. Paired pre- and post-trastuzumab blood and tissue samples from patients with gastric cancer treated with trastuzumab were analyzed. We found that resistant cells were associated with increased activation of MAPK/ERK and PI3K/mTOR pathways driven by SRC activation. Upstream, resistant cells showed increased coexpression of multiple HER-family ligands that allowed for compensatory activation of alternative HER receptors upon HER2 blockade. Simultaneous inhibition of EGFR, HER2, and HER3 by the novel antibody mixture, Pan-HER, effectively reverted trastuzumab resistance in vitro and in vivo Similarly, an increase in HER-family ligands was observed in serum and tumor from patients with gastric cancer after trastuzumab therapy. We propose that trastuzumab resistance in gastric cancer is mediated by HER-family ligand upregulation that allows a compensatory activation of HER receptors and maintains downstream signaling activation despite trastuzumab therapy. Resistance is reverted by simultaneous inhibition of EGFR, HER2, and HER3, thereby revealing a potential therapeutic strategy to overcome trastuzumab resistance in patients with gastric cancer.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher American Association for Cancer Research (AACR)
dc.relation.ispartof Molecular Cancer Therapeutics. 2019 Nov;18(11):2135-45
dc.rights © American Association for Cancer Research (AACR) http://dx.doi.org/10.1158/1535-7163.MCT-19-0455
dc.subject.other Aparell digestiu -- Càncer -- Tractament
dc.title HER-family ligands promote acquired resistance to trastuzumab in gastric cancer
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1158/1535-7163.MCT-19-0455
dc.rights.accessRights info:eu-repo/semantics/embargoedAccess
dc.type.version info:eu-repo/semantics/acceptedVersion
dc.embargo.liftdate 2020-11-30
dc.date.embargoEnd info:eu-repo/date/embargoEnd/2020-11-30

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


Compliant to Partaking